CeriBell's (NASDAQ:CBLL) Lock-Up Period Set To End on April 9th

CeriBell's (NASDAQ:CBLL - Get Free Report) lock-up period is set to end on Wednesday, April 9th. CeriBell had issued 10,606,060 shares in its public offering on October 11th. The total size of the offering was $180,303,020 based on an initial share price of $17.00. After the expiration of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Analyst Ratings Changes

CBLL has been the subject of a number of research analyst reports. Canaccord Genuity Group reissued a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. TD Cowen increased their target price on shares of CeriBell from $31.00 to $36.00 and gave the stock a "buy" rating in a research report on Monday, December 9th. Finally, LADENBURG THALM/SH SH started coverage on shares of CeriBell in a report on Friday. They set a "buy" rating and a $32.00 price target on the stock. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has a consensus rating of "Buy" and an average target price of $32.50.

CeriBell Stock Down 1.5 %

CBLL stock traded down $0.29 during trading hours on Friday, hitting $18.44. The company's stock had a trading volume of 182,944 shares, compared to its average volume of 239,277. The stock has a 50 day moving average of $21.95. CeriBell has a 12 month low of $17.67 and a 12 month high of $32.75.

Remove Ads

CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings data on Tuesday, February 25th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by ($0.08). The company had revenue of $18.53 million for the quarter, compared to analyst estimates of $17.55 million. On average, research analysts expect that CeriBell will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in CBLL. Woodline Partners LP bought a new stake in CeriBell during the fourth quarter worth approximately $2,588,000. Yu Fan bought a new stake in shares of CeriBell during the 4th quarter worth $31,631,000. TPG GP A LLC bought a new position in CeriBell in the 4th quarter worth approximately $102,677,000. RTW Investments LP acquired a new position in shares of CeriBell during the fourth quarter worth approximately $3,882,000. Finally, Red Tree Management LLC bought a new stake in shares of CeriBell in the fourth quarter valued at approximately $57,083,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.